Conquering Diseases

A Study To Compare Standard Chemotherapy To One Or More Investigational Drugs For Patients With Newly Diagnosed Aml

Description

Seeking male and female participants who are under 22 years of age at enrollment with newly diagnosed de novo AML (a cancer of the bone marrow) for participation in a study comparing standard chemotherapy to one or more investigational drugs.

Overview

We are studying a combination of one or more investigational drugs in addition to chemotherapy for patients newly diagnosed with AML. Treatment for AML involves high doses of a common class of chemotherapy drugs, but can have long term side-effects. We are interested in finding an effective treatment for AML that reduces the potential long term side effects.

What we're hoping for

To evaluate the safety and efficacy of the drugs CPX-351 with daunorubicin and cytarabine and gilteritinib on people with newly diagnosed AML, to determine which is better.

Additional Information

ClinicalTrials.gov Identifier: NCT04293562

 Principal Investigator

Stefanie  Lowas, MD

University of Massachusetts Medical School

 Study Contact

The Cancer  Research Office

508-856-3216

Cancer.research@umassmed.edu

 Location

UMMS University Campus

55 Lake Ave North 

Worcester,MA 01655

508-856-8989